Human nerve growth factor (NGF) can be involved in the transmission and sensation of inflammation and neuropathic pain, and anti-NGF treatment can relieve these symptoms. tanezumab, meanwhile, is a fully human monoclonal antibody that neutralizes NGF and is currently in clinical trials for the treatment of chronic pain, and NGF binds to tanezumab very reliably.